Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2022

Phase 2 STORM Trial Shows Positive Outcomes

Francis Price, MD

Show Description +

Francis Price, MD, shares positive data from the phase 2 STORM trial by Trefoil Therapeutics, which examined if treatment with an engineered fibroblast growth factor led to quicker resolution of edema and improved visual acuity for patients undergoing a Descemet stripping only procedure for Fuchs dystrophy.

Posted: 10/03/2022

Keywords:

Trefoil Therapeutics

•

Clinical Trials

•

fibroblast growth factor

•

edema

•

Visual Acuity

•

Descemet stripping only

•

Fuchs endothelial corneal dystrophy

Up Next

Documenting for Patient Care

Documenting for Patient Care

Bradley Henriksen, MD

Mask-Associated Dry Eye Syndrome

Mask-Associated Dry Eye Syndrome

New Devices in Glaucoma

New Devices in Glaucoma

Oluwatosin Smith, MD, and Qi Cui, MD

Optics 101: Matching Optics to Available Technology

Optics 101: Matching Optics to Available Technology

Julie Schallhorn, MD

One-Year Visual Outcomes Following Monocular Implantation With a Small-Aperture IOL

One-Year Visual Outcomes Following Monocular Implantation With a Small-Aperture IOL

Mark Blecher, MD

The FDA Perspective: The Link Between Medical Devices and Patients

The FDA Perspective: The Link Between Medical Devices and Patients

Michelle E. Tarver, MD

The Six Traits of an Inclusive Practice Leader

The Six Traits of an Inclusive Practice Leader

Rupa Wong, MD

$A Refractive Surgery Journey and Lessons Learned$

A Refractive Surgery Journey and Lessons Learned

Sheraz M. Daya, MD, FACP, FACS, FRCS(Ed), FRCOphth

A Look at a New Shape-Changing IOL

A Look at a New Shape-Changing IOL

Eric D. Donnenfeld, MD

IOL Calculations: The Internet Way

IOL Calculations: The Internet Way

Oliver Findl, MD, MBA

Corneal Ulceration in Patients With Ocular Graft-Versus-Host Disease

Corneal Ulceration in Patients With Ocular Graft-Versus-Host Disease

Rahul Tonk, MD; Paula Sepulveda, MD

Evaluating the Efficacy of a ROCK Inhibitor for the Treatment of Corneal Edema

Evaluating the Efficacy of a ROCK Inhibitor for the Treatment of Corneal Edema

Himani Goyal, MD; Adanna Udeh, MD

Dr. Avery’s AAO 2022 Can’t-Miss Retina Sessions

Dr. Avery’s AAO 2022 Can’t-Miss Retina Sessions

Robert L. Avery, MD

Ocular Inflammation in Retinal Gene Therapies

Ocular Inflammation in Retinal Gene Therapies

Glenn C. Yiu, MD, PhD

The State of Macular Hole Surgery

The State of Macular Hole Surgery

Sophie J. Bakri, MD

A Look at Private Equity in Retina

A Look at Private Equity in Retina

John T. Thompson, MD

Avoid PDR Complications With Early Vitrectomy

Avoid PDR Complications With Early Vitrectomy

Maria H. Berrocal, MD

GA Update: Phase 3 Data for Pegcetacoplan

GA Update: Phase 3 Data for Pegcetacoplan

Charles C. Wykoff, MD, PhD

Phase 2/3 Data for High-Dose Aflibercept for DME

Phase 2/3 Data for High-Dose Aflibercept for DME

David M. Brown, MD

Protocol AC Guides DME Treatment Approaches

Protocol AC Guides DME Treatment Approaches

Chirag D. Jhaveri, MD

How to Deploy Home OCT

How to Deploy Home OCT

Nancy M. Holekamp, MD

Back to All Videos

Phase 2 STORM Trial Shows Positive Outcomes

Francis Price, MD

Francis Price, MD, shares positive data from the phase 2 STORM trial by Trefoil Therapeutics, which examined if treatment with an engineered fibroblast growth factor led to quicker resolution of edema and improved visual acuity for patients undergoing a Descemet stripping only procedure for Fuchs dystrophy.

Posted: 10/03/2022

Keywords:

Trefoil Therapeutics

•

Clinical Trials

•

fibroblast growth factor

•

edema

•

Visual Acuity

•

Descemet stripping only

•

Fuchs endothelial corneal dystrophy

Please log in to leave a comment.

More From AAO: 2022 Coverage

Ocular Inflammation in Retinal Gene Therapies

Ocular Inflammation in Retinal Gene Therapies

Glenn C. Yiu, MD, PhD

The State of Macular Hole Surgery

The State of Macular Hole Surgery

Sophie J. Bakri, MD

A Look at Private Equity in Retina

A Look at Private Equity in Retina

John T. Thompson, MD

Avoid PDR Complications With Early Vitrectomy

Avoid PDR Complications With Early Vitrectomy

Maria H. Berrocal, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2022.